[www.bloomberg.com]@ wrote:
The Covid-19 vaccine being developed by Pfizer Inc. and BioNTech SE prevented more than 90% of infections in a study of tens of thousands of volunteers, the most encouraging scientific advance so far in the battle against the coronavirus. . .
The findings are based on an interim analysis conducted after 94 participants contracted Covid-19. The trial will continue until 164 cases have occurred. If the data hold up and a key safety readout Pfizer expects in about a week also looks good, it could mean that the world has a vital new tool to control a pandemic that has killed more than 1.2 million people worldwide.
“This is about the best the news could possibly be for the world and for the United States and for public health,” said William Gruber, Pfizer senior vice president for vaccine clinical research and development. It was better than even the best result he had hoped for, he said. . .
The data do have limits. For now, few details on the vaccine’s efficacy are available. It isn’t known how well the shot works in key subgroups, such as the elderly. Those analyses haven’t been conducted. And it isn’t known whether the vaccine prevents severe disease, as none of the participants who got Covid-19 in this round of analysis had severe cases, Gruber said.
People possibly getting too excited too soon?@ wrote:
“Dr. Jansen said the outside board did not say how many of those cases came from participants who had been vaccinated. But with a rate of more than 90% effectiveness, most had to have been in the placebo group.”
Yeah, 90% is about as close to a gold standard as possible. Early projections were hoping for even 50% efficacy. That was something I was aware of.@walesmaven wrote:
Actually the statistics support early confidence. Remember, no one expects 100% protection from any vaccine.
@Flash wrote:
Even if it was 100% in trials, this is a vaccine that has issues as it apparently needs to be kept at -80. Dry ice is only -78 if I recall correctly. Distribution with it staying viable will be quite an issue.
As noted above (to walesmaven), it wasn't so much being in trials that was at issue in my "worry post," but rather that Pfizer had not broken down what the 90% meant in regards to vaccinated vs. placebo group prevention efficacy and infection rates.@Flash wrote:
Even if it was 100% in trials, this is a vaccine that has issues as it apparently needs to be kept at -80. Dry ice is only -78 if I recall correctly. Distribution with it staying viable will be quite an issue.
I wonder how this affects Third World vaccination. Laurie Garrett (Pulitzer Prize winning journalist in medicine), B.S. Biology (UC Santa Cruz), Ph.D. studies*** in Immunology (Berkeley) has raised concerns about the need for refrigeration.@SoCalMama wrote:
Problem is that Americans never were able to switch to the metric system in the 1970's.@Flash wrote:
Even if it was 100% in trials, this is a vaccine that has issues as it apparently needs to be kept at -80. Dry ice is only -78 if I recall correctly. Distribution with it staying viable will be quite an issue.
-70C = -94F, Required temp of the vaccine.
Dry ice sublimates at -78C = -109F
Liquid Nitrogen is -196C
I'm sure that is the least of their worries. Scientists don't use English measurements.
@shoptastic wrote:
Yeah, 90% is about as close to a gold standard as possible. Early projections were hoping for even 50% efficacy. That was something I was aware of.@walesmaven wrote:
Actually the statistics support early confidence. Remember, no one expects 100% protection from any vaccine.
[www.nytimes.com] (quote was originally from here)
I think the part I highlighted that was debated on fintwit this morning was a possible misunderstanding of what was being said in the quotes (from the article linked here). We know from the study that 50% of participants got two doses of the vaccine and 50% were the placebo group (getting nothing). Pfizer has not release who got what and the question was what this 90% number meant (e.g., from which group were the infections coming from and at what rate).
I think the fear was that maybe people got the virus equally in both groups (or worse), meaning the vaccine had no effect or less effect that advertised. I saw other weird debates this morning too on what various parts of the study meant (as Pfizer, again, had not released details).
But, that wouldn't make sense for the unanimous euphoric medical community reaction if the vaccine didn't have such high efficacy. Until otherwise informed, I take the news in its best interpretation: that the vaccine is producing 90% prevention efficacy in those taking it. They note that this rate is subject to change over time, but the initial news is no doubt quite stunning.
@SoCalMama wrote:
@Flash wrote:
Even if it was 100% in trials, this is a vaccine that has issues as it apparently needs to be kept at -80. Dry ice is only -78 if I recall correctly. Distribution with it staying viable will be quite an issue.
Problem is that Americans never were able to switch to the metric system in the 1970's.
-70C = -94F, Required temp of the vaccine.
Dry ice sublimates at -78C = -109F
Liquid Nitrogen is -196C
I'm sure that is the least of their worries. Scientists don't use English measurements.
@Flash wrote:
It is true that most of the world works on metric measures while the US does not, but in reality science tends to work in Kelvin for temperatures.
@Flash wrote:
Even if it was 100% in trials, this is a vaccine that has issues as it apparently needs to be kept at -80. Dry ice is only -78 if I recall correctly. Distribution with it staying viable will be quite an issue.
@Shop-et-al wrote:
This is one reason the research process is lengthy.
Anyone planning to do one of these?@ wrote:
"While COVID-19 diagnostic tests have been authorized for at-home collection, this is the first that can be fully self-administered and provide results at home," FDA Commissioner Dr. Stephen Hahn said in a statement. . .
But some health experts urged caution.
"The data is just still emerging, Tom Bollyky, the director of the global health program and senior fellow for global health, economics, and development at the Council on Foreign Relations, told CNN. "Obviously with some past emergency use authorizations it pays to be cautious with what the FDA has put out here, but it's certainly a promising sign."